

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 286)**

### **UPDATE ON PROFIT TARGET ON DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF A MEDICAL BEAUTY ANTI-AGING GROUP AND ISSUE OF SHARES UNDER GENERAL MANDATE**

Reference is made to the announcements of the Company dated 12 August 2017, 24 August 2017, 9 September 2017 and 9 October 2017 in relation to a discloseable transaction for the acquisition of a medical beauty anti-aging group and issue of shares under general mandate (the “**Announcements**”) of Common Splendor International Health Industry Group Limited (the “**Company**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

#### **PROFIT TARGET IN RESPECT OF THE TARGET GROUP AND LOCK-UP UNDERTAKING**

The Board announces that the audited consolidated net profit of the Target Group for the twelve-month period ended 31 October 2018 was approximately HK\$26.8 million, which is higher than HK\$25 million, and the parties to the Agreement agreed that the relevant net profit guarantee in respect of the Target Group has been fulfilled. Accordingly, the first tranche Consideration Shares issued to Vendor B, Vendor C, Vendor D, Vendor E, Vendor F and Vendor G in October 2017, being 290,000,000 Shares, in aggregate, are no longer subject to the relevant lock-up undertaking.

The remaining Consideration Shares, being 90,000,000 Shares, in aggregate, shall remain to be subject to the respective lock-up undertaking from each of Vendor B, Vendor C, Vendor D, Vendor E, Vendor F and Vendor G pending fulfilment of the Target Group's relevant profit target. Please refer to the Announcements for information on the Company's shareholding structure immediately after the issuance of the Consideration Shares in full and the Target Group's profit target.

By Order of the Board of  
**Common Splendor International  
Health Industry Group Limited**  
**Cheung Wai Kuen**  
*Chairman*

Hong Kong, 3 January 2019

*As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Hou Kai Wen and Mr. Lin Jiang as non-executive Directors; and Mr. Lam Chi Wing, Mr. Mai Yang Guang, and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.*